TAXUS IV is a pivotal trial designed to collect data to support regulatory filings for U.S. product commercialization. The prospective, randomized, double-blind study will assess the safety and efficacy of a slow-release dose formulation paclitaxel-eluting TAXUS™ stent system for the treatment of coronary restenosis. The TAXUS IV trial is using the Express™ stent, a laser-cut, balloon-expandable stent developed exclusively by Boston Scientific.

"We are encouraged by both the enthusiasm the investigator community has shown for our technology and the rapid pace of enrollment," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "As we begin follow-up on the largest patient population we have enrolled to date, we remain strongly committed to further demonstrating the safety and effectiveness of this innovative therapy."

The TAXUS program is a series of clinical studies designed to collect data on Boston Scientific's proprietary paclitaxel-eluting stent technology for reducing coronary restenosis, the growth of tissue within an artery after angioplasty and stenting. Paclitaxel, the active component of the popular chemotherapeutic agent Taxol®, has demonstrated promising results in pre-clinical and clinical studies for reducing the processes leading to restenosis.

The TAXUS I trial confirmed safety and reported zero thrombosis and zero restenosis. The TAXUS II trial completed enrollment of 537 patients in January, and the patients are now in the follow-up period. Preliminary safety data from TAXUS II presented in March at the American College of Cardiology annual meeting provided further support for the safety of paclitaxel-eluting stents. The TAXUS III trial studied the treatment of in-stent restenosis and also confirmed safety with no thrombosis. Boston Scientific has also initiated a transitional registry program (WISDOM) in a number of countries as part of a limited commercial launch of its TAXUS™ Express™ paclitaxel-eluting stent system.

Boston Scientific remains positioned to launch paclitaxel-eluting stents in Europe this year and in the U.S. in 2003.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices. The Company's products are used in a broad range of interventional medical specialties.

This press release contains forward-looking statements. The Company wishes to caution the reader that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, physician acceptance of new products, competitive product offerings and other factors described in the Company's filings with the Securities and Exchange Commission.